{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-003704","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.298064+00:00","generated_at":"2026-06-04T11:09:30.700373+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Armata Pharma Q4 loss $9.6M; secures $35M loan at 14%, matures June 2025","bullets":["Q4 2023 loss from operations $(9.6)M vs $(10.3)M in Q4 2022; cash $13.5M at Dec 31, 2023.","Entered $35M credit agreement with Innoviva SO on March 4, 2024; 14% annual rate, matures June 4, 2025.","Phase 2 diSArm study of AP-SA02 for Staph aureus bacteremia continues dose escalation; Phase 2 Tailwind study of AP-PA02 for NCFB progressing.","Manufacturing facility advanced; R&D labs completed; five cGMP suites expected H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-003704","json":"https://secwatch.observer/filing/0001558370-24-003704.json","markdown":"https://secwatch.observer/filing/0001558370-24-003704.md","text":"https://secwatch.observer/filing/0001558370-24-003704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000155837024003704/0001558370-24-003704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000155837024003704/armp-20240321x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:09:30.700373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9da8c752c3b0baae26b0fe28ca9629f15d74b8f","claim":"Armata Pharmaceuticals, Inc. reported the three months and full fiscal year ended December 31, 2023 results: revenue approximately $1.5 million.","evidence_excerpt":"what we are poised to achieve this year and next,” Dr. Birx concluded. Fourth Quarter 2023 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.5 million for the three months ended December 31, 2023, which represents Medical Technology Enterprise Consortium’s share of the costs incurred for the Company’s AP-SA02 program for the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000155837024003704/0001558370-24-003704-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and full fiscal year ended December 31, 2023"},{"label":"Revenue","value":"approximately $1.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}